Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson’s Disease

Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson’s Disease

Zonisamide is a relatively recent drug for Parkinson’s disease. Multiple hypotheses have been proposed to explain the antiparkinsonian effects of zonisamide. However, it is still unclear whether the effect of zonisamide is mainly due to dopaminergic modification in the striatum, or if zonisamide wor...

Full description

Bibliographic Details
Main Authors:	Haruo Nishijima, Yasuo Miki, Shinya Ueno, Masahiko Tomiyama
Format:	Article
Language:	English
Published:	Hindawi Limited 2018-01-01
Series:	Parkinson's Disease
Online Access:	http://dx.doi.org/10.1155/2018/8626783

Similar Items

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
by: Angelo Antonini
Published: (2009-05-01)

What mechanisms are responsible for the reuptake of levodopa-derived dopamine in parkinsonian striatum?
by: Haruo Nishijima, et al.
Published: (2016-12-01)

Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia
by: Tatsuya Ueno, et al.
Published: (2014-04-01)

Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2012-01-01)

Apomorphine in Parkinson's disease—The questions raised
by: Rajinder K Dhamija, et al.
Published: (2020-01-01)

Somatosensory Evoked Potentials and Dopaminergic Responsiveness to Apomorphine and Levodopa in Parkinsonian Patients
by: M. Miranda, et al.
Published: (1996-01-01)

Apomorphine subcutaneous infusion, duodenal infusion of levodopa and deep brain stimulation – three advanced treatment options for the advanced Parkinson’s disease
by: Dušan Flisar, et al.
Published: (2016-10-01)

Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease
by: Keisuke Suzuki, et al.
Published: (2021-03-01)

Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease
by: Ewa Papuć, et al.
Published: (2019-03-01)

Apomorphine in the treatment of Parkinson's disease: a review
by: Renata Ramina Pessoa, et al.

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
by: Felix Agbo, et al.
Published: (2021-07-01)

Zonisamide for the Treatment of Parkinson Disease: A Current Update
by: Chengqian Li, et al.
Published: (2020-12-01)

Review: A review of the use of zonisamide in Parkinson’s disease
by: Pedro Emilio Bermejo, et al.
Published: (2009-09-01)

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease
by: Shin-Ichi Ueno, et al.
Published: (2018-12-01)

Pharmacokinetic and pharmcodynamic studies of apomorphine in the treatment of idiopathic Parkinson's disease
by: Ingram, Wendy Merewyn
Published: (2001)

Gene polymorphisms and motor levodopa‐induced complications in Parkinson's disease
by: Małgorzata Michałowska, et al.
Published: (2020-03-01)

Neural mechanisms of Levodopa induced motor complications in Parkinson’s disease
by: Bowden, Gregory Neil
Published: (2009)

Neural mechanisms of Levodopa induced motor complications in Parkinson’s disease
by: Bowden, Gregory Neil
Published: (2009)

Subcutaneous apomorphine in advanced Parkinson’s disease and its use in Indian population
by: Vinod Metta, et al.
Published: (2020-01-01)

Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
by: Nrupa Borkar, et al.
Published: (2018-11-01)

Levodopa for treatment of parkinson’s disease
by: M. Petraru, et al.
Published: (2011-09-01)

Prosody and levodopa in Parkinsons disease
by: Luciana Lemos de Azevedo, et al.
Published: (2013-11-01)

Clinical Utility of Skin Biopsy in Differentiating between Parkinson’s Disease and Multiple System Atrophy
by: Rie Haga, et al.
Published: (2015-01-01)

Levodopa-Responsive Benign Tremulous Parkinsonism
by: Osamu Kano, et al.
Published: (2013-08-01)

Prosodic expression and levodopa in Parkinson's disease
by: Mara Behlau
Published: (2013-11-01)

Mortality in Levodopa-Treated Parkinson's Disease
by: John C. Morgan, et al.
Published: (2014-01-01)

Turmeric active substance, curcumin, enhanced apomorphine-induced yawning in rats
by: Esmaeal Tamaddonfard
Published: (2013-05-01)

Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
by: Shigeki Arawaka, et al.
Published: (2014-01-01)

Investigation of apomorphine during sleep in Parkinson’s: Improvement in UPDRS Scores
by: Miguel A. Pieroni
Published: (2019-12-01)

Mathematical modeling and parameter estimation of levodopa motor response in patients with parkinson disease.
by: Mauro Ursino, et al.
Published: (2020-01-01)

Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatment
by: Kasemsap N, et al.
Published: (2016-05-01)

Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease
by: Frédéric Calon, et al.
Published: (2003-12-01)

Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson’s Disease
by: Miguel M. Carvalho, et al.
Published: (2017-08-01)

Levodopa versus non-levodopa brain language fMRI in Parkinson's disease
by: Paula Ricci Arantes, et al.

Levodopa versus non-levodopa brain language fMRI in Parkinson’s disease
by: Paula Ricci Arantes, et al.
Published: (2012-06-01)

Apomorphine Penject – Emerging Evidence and Treatment Strategies for Delayed on and off Periods in Parkinson’s disease
by: Olivier Rascol, et al.
Published: (2014-07-01)

Levodopa in the treatment of Parkinsonism
by: Hunter, K. R.
Published: (1975)

Effects of Aging on Levo-Dihydroxyphenylalanine- Induced Dyskinesia in a Rat Model of Parkinson’s Disease
by: Haruo Nishijima, et al.
Published: (2021-05-01)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
by: Fatma Haddad, et al.
Published: (2017-12-01)

Modulation of habit formation by levodopa in Parkinson's disease.
by: Frank Marzinzik, et al.
Published: (2011-01-01)